The traditional treatment includes pioglitazone, a type of insulin-sensitizing agent, which could improve liver biochemical and histological parameters in patients with nonalcoholic steatohepatitis (NASH). Here, INS is linked to metabolic dysfunction-associated steatohepatitis.